Anna F. Farago, MD, PhD
Advertisement
Articles by Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Latest Updated Articles
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLCPublished: June 11th 2019 | Updated:
Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung CancerPublished: June 12th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients
5